Significant correlation was found between systolic blood pressure (r: 0.239, p: 0.007) and duration of diabetes with
homocysteine (r: 0.302, p: 0.001).
If
homocysteine accumulates in the bloodstream, however, a host of problems follow.
Participants in both groups were evaluated for plasma
homocysteine levels, by collection into a heparinized tube and later transferred in ice blocks.
An article published in 2017 reported on the growing epidemiological evidence of a strong association between elevated
homocysteine and hearing loss.
Meta-analysis of cross-sectional studies have suggested that increased serum
Homocysteine concentration is associated with 60 percent increase in the incidence of cardiovascular diseases.
Despite the accumulating evidence describing the effect of
homocysteine on CV function, few studies with conflicting results have examined CV effects of
homocysteine in rheumatoid arthritis.
Increasing plasma
homocysteine level is associated with elevating the risk of systemic vascular disease through enhancement of the adverse effects of risk factors such as hypertension, smoking, and lipid and lipoprotein metabolism, as well as acceleration of development of inflammation.
DNA methylation has long been recognized as an epigenetic silencing mechanism and plays important roles in many cellular processes, such as gene transcription, genomic imprinting, and X-chromosome inactivation.[sup][3]
Homocysteine is an amino acid produced in the liver after the metabolism of methionine.
Homocystinuria is the term used for several rare genetic disorders (diseases passed down through families) that cause levels of
homocysteine to build up in blood and urine.
Homocysteine is a non-protein-forming sulfur-containing amino acid first described by Butz and du Vigneaud in 1932.